The Q3 2024 Strategic Insights Report delivers an unparalleled analysis of the funding, M&A, and licensing activities redefining the biopharma landscape.
With exclusive data from Beacon, this report reveals:
- A 25% surge in $100M+ funding rounds, highlighting a shift toward larger investments.
- The dominance of bispecific drug development, leading M&A transactions with $19.5B in upfront payments.
- The rise of RNA therapies in high-value licensing agreements.
Stay ahead of the curve with actionable insights tailored to your needs. Whether you’re driving innovation, navigating investment opportunities, or scaling your operations, this report is your roadmap to success.
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
